PHARVARIS N.V. EO -12 Cash Flow Conversion Efficiency
PHARVARIS N.V. EO -12 cash flow conversion efficiency. Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-37.95 Million ≈ $-44.37 Million USD) by net assets (€271.27 Million ≈ $317.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PHARVARIS N.V. EO -12 (2021–2025)
Cash flow conversion efficiency of PHARVARIS N.V. EO -12 from 2021 to 2025. This chart illustrates how PHARVARIS N.V. EO -12's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHARVARIS N.V. EO -12 (9EN) share price today for real-time trading data and today's change.
PHARVARIS N.V. EO -12 Cash Flow Conversion Ratio Explained
PHARVARIS N.V. EO -12 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PHARVARIS N.V. EO -12 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their cash flow conversion efficiency. Also see 9EN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pebblebrook Hotel Trust
NYSE:PEB
|
0.033x |
|
Jiaozuo Wanfang Aluminum
SHE:000612
|
0.020x |
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
0.001x |
|
BlackRock Science and Technology Trust II
NYSE:BSTZ
|
-0.019x |
|
Alkane Resources Ltd
AU:ALK
|
0.156x |
|
Beijing TRS Information Tech
SHE:300229
|
-0.003x |
|
Pimco Dynamic Income Opportunities Fund
NYSE:PDO
|
0.276x |
|
Chambal Fertilizers & Chemicals Limited
NSE:CHAMBLFERT
|
0.033x |
Annual Cash Flow Conversion Efficiency for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARVARIS N.V. EO -12 from 2021 to 2025. Review PHARVARIS N.V. EO -12 (9EN) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €271.27 Million ≈ $317.15 Million |
€-137.07 Million ≈ $-160.25 Million |
-0.505x | -12.63% |
| 2024-12-31 | €267.76 Million ≈ $313.04 Million |
€-120.13 Million ≈ $-140.44 Million |
-0.449x | -85.17% |
| 2023-12-31 | €384.05 Million ≈ $448.99 Million |
€-93.05 Million ≈ $-108.78 Million |
-0.242x | +46.16% |
| 2022-12-31 | €149.26 Million ≈ $174.50 Million |
€-67.16 Million ≈ $-78.52 Million |
-0.450x | -106.78% |
| 2021-12-31 | €204.95 Million ≈ $239.61 Million |
€-44.60 Million ≈ $-52.14 Million |
-0.218x | -- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more